The global central nervous system treatment market size is anticipated to reach USD 166.53 billion by 2028 and exhibit a CAGR 0f 9.4% during the forecast period. The increasing geriatric population and the associated neurological disorders are likely to fuel the market growth in the coming years. Fortune Business InsightsTM has presented this information in its report titled “Central Nervous System Treatment Market, 2021-2028”.
The central nervous system treatment market size stood at USD 81.67 billion in 2020 and is estimated to reach USD 89.02 billion in 2021.
The prospective product launches to treat neurological disorders are expected to boost the market growth during the forecast period. The new product launches are likely to augment treatment access in developing nations, favoring the market growth.
Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/central-nervous-system-treatment-market-103973
| North America | United States, Canada and Mexico |
| Europe | Germany, UK, France, Italy, Russia and Turkey etc. |
| Asia-Pacific | China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam etc. |
| South America | Brazil, Argentina, Columbia etc. |
| Middle East & Africa | Saudi Arabia, UAE, Egypt, Nigeria and South Africa |
Rising Prevalence of Neurological Disorders & Launch of New Products to Propel Market Growth
The increasing prevalence of neurological disorders, including Parkinson’s Alzheimer’s, multiple sclerosis, and others, coupled with the expanding geriatric population, is anticipated to boost the global central nervous system treatment market growth. The Alzheimer’s Association estimates approximately 14 million cases by 2050. This is anticipated to boost the market growth significantly. Additionally, the launch of new prospective products and pipeline drugs is expected to create lucrative growth opportunities for the market. The new product launches are likely to augment the access to treatment in developing nations, thereby fueling the market growth.
Segmentation
On the basis of disease type, the market is fragmented into infectious diseases, mental health, neurodegenerative diseases, neurovascular diseases, and others. On the basis of drug class, the market is segmented into immunomodulatory drugs, interferons, analgesics, antidepressants, dopamine agonists, decarboxylase inhibitors, and others. On the basis of drug type, the market is bifurcated into non-biologics and biologics. On the basis of distribution channels, the market is trifurcated into online pharmacies, retail pharmacies, and hospital pharmacies. Geographically, the market is classified into Asia Pacific, Latin America, North America, Europe, and the Middle East & Africa.
Report Coverage
- It offers valuable insights into the market’s regulatory scenarios.
- It assimilates information on the latest market trends and industry developments.
- It incorporates SWOT Analysis for precise prediction.
- It sheds light on the COVID-19 pandemic’s effect on the market.
- It highlights strategies adopted by key players to acquire growth.
Speak To Our Analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/central-nervous-system-treatment-market-103973
Related Reports :
Hunter Syndrome Treatment Market Size to reach USD 1118.4 Million | Rising in United States and United Kingdom | Fortune Business Insights
Immune Health Supplements Market is projected to reach USD 29.40 billion by 2027
Internet of Medical Things (IoMT) Market is anticipated to reach USD 142.45 billion by 2026, with a CAGR of 28.9%
Spirometer Market Size to reach USD 716.8 Million [CAGR 4.7%] | Fortune Business Insights
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245